{"name":"Ensysce Biosciences","slug":"ensysce-biosciences","ticker":"","exchange":"","domain":"ensysce.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5210031,"revenueGrowth":133.6,"grossMargin":0,"rdSpend":7219437,"netIncome":2404519,"cash":5597232,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNWE13UWg0d1UtcXpDY1BhTEwtNFUzU0pxWC1PcDgySUsxblBXai1aSkdrNmphaUtEQVRrVi04VzBGMUwwaG9YYVFiUGpoR0JFWTNaYldhWENyX3ZWRHJDSC1jdU5uM2FfN2Y3YkpHTVQ5VzVub2I1QUI3X3Frd3k3MndoU3k4eFIyNG5hT2JGNElYV1pMRzFyeU1kZmlhYlp0RG1IYmlIQkdmQmY4bjZ4UHkzaklVVTVETVVuZHlhQXJlUGRPWFVGeFRSa1dDVHdiOXV3cWJVenlUQWZpN3VFbk1RVXZPbFRzelNVZg?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart.com","summary":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOdE1UODhjMUdqa290THo4M1c5QVU5VVluYXNkTG5fSks2S3ZWTXFqNnRsS2p2SVRrMlVyNmpod0Q4OE9SWjM1OW4wRUhpSWdMZDR0cEs4MkU4ZmdZOHZuZTFvNjFuRFNfd2syLWU1dG03dVRwM0phT1RJSl9VeWxPclVyVjczMEt6S2o5R0xBdHJnakNRbmdMM0cyZGE4a0lZVUp6UDVHcVZJSjh1dVNWeHRDWGN2ckU?oc=5","date":"2026-03-30","type":"earnings","source":"National Today","summary":"Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today","headline":"Ensysce Biosciences Reports Q4 and Full Year 2025 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBvc3VFaDczbjBCRzdCM2JfYVdHMVF6MERLUFFsZ2RKcHdVYmhVUU5NTEFXVm8yOXdmdVp4UGlzak4xUTNMN2d1dnhnQTVWdUNHdHY3d2NubWF1TVNqLXfSAWNBVV95cUxQV1hNbnI4ejlrQXUwTlVabUtvYXM2ck8ydUZTTTFPTG10aTBjd0FCYjdXU2ZiTWpVa25ZTGtTWEJJTmY5dGtnbDhsMnFnMWhFZkMyMm1hbl9yLVdSRjg1eEhWZFU?oc=5","date":"2026-03-30","type":"earnings","source":"Bitget","summary":"Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget","headline":"Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQbnZqQlJzaERlc0lMQWF1Uk11XzY5OTdsZGNIekpLbnpGWFdwMUdQNDkzR0JvUlViM290ai1HdXBNVzJ3NmJhTGRmZkhVZE1WMDdYTmdBRGJBdEVaM2l2VFVKYW9hVnhhMm00cGxheWVadjdlVFJtY1E0VnNKSUE5YlNudG5vb1B5SjRCMzNDU256bndPQk1nMklSLVp2LU9ZNEVXNE9qU1lOYnRkekhScXR4aThHcEFDdlBWelJRUk1MRnBmT1MwSVgwREZodGlQ?oc=5","date":"2026-03-30","type":"earnings","source":"ChartMill","summary":"Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - ChartMill","headline":"Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5BZTFGa0M0UGdSbmdST1UwTUZsZmtBanMwTWNKbWRLalBwb2ZkUXNFOXFpUV94dHdmamFRbkd3RWg0THctZzlMaDloS2ZDLW9qNV93UThQVU9aTTBRdEZhOVRRbHJXTy1Dd2VkQ3pR?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan","headline":"If You Invested $1,000 in Ensysce Biosciences Inc (ENSC)","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOblhRQlFGazlpTmRic1BFdDRHN1h1OWVDbWh4SWxSSlZBVHJSVWNkUGlQMEZrbGwwWTJSbDVuUVFvZERIeWpWYy1DOFJ2Wnp3X2hKSmlKeTM5VlJZMEJmNlZ2b0hPYndocGU5OVhPUzIyVkVMb3prVGVzUl9LNTNSZXhkRGNoQWNPZ2pfeXEtT0tvUHNMXzNfNFFHaThnNVU3ckFPYWloVDJPX05seFJ5ZU9DTFRXUQ?oc=5","date":"2026-03-03","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Adial Pharmaceuticals (NASDAQ:ADIL), Ensys - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Adial Pharmaceuticals (NASDAQ:ADIL), Ensys","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxONE1lV0hObTI1b3BpT0F5TlloTzgtUFdiMENuT0Z3Y0FWNF9mZE1WaDBoN2NObkxqcnBWLUFjQUJ1STJ2VDByLWdMOW5OQXYzcWtZQjl1bXRidG5fS2N1UEpOd0FBN055ckpONVdkZ1lNSlhLc1dzMGZOSDcyVDZZS05RNjBZd3gtbThKdHpGd0QtWFV1TTh3dXV2Ql8wVGl4WVhDWExTMlFRMFYxVVFBZVFQUWFjZGx5M2RhcWdMY19ERXNGMUlvZVRVNA?oc=5","date":"2026-02-27","type":"pipeline","source":"Benzinga","summary":"Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga","headline":"Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPVm9PcG52eDNsc3JyOXJmaHU1eWtJbnNuVGt6R0p5aVdTLWdVcmEtaDZBMFpLWEtXS2ZxX2xqejlZczZrSlg2aERNT0VXWjA1NWQ1Zk1OVV9qSVpZN1daQ1FFZWtXTVBqV3J6U21mNnRtbWxIRG5rS0NmVmVIdDRWR0NLY292a29OUHNPN01XR01JbE9hNmpXbTZaS2N3UlRfLWtFcWxHaVNMMFlrLUtKY2F1QkVwenhYZFNtODFob3RUYTlsVkpRUzFPZWlpeF9BWngwczdha3JpbmNWcTA2NQ?oc=5","date":"2026-02-25","type":"pipeline","source":"ChartMill","summary":"Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - ChartMill","headline":"Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5210031,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":5210031,"period":"2024-12-31"},{"value":2230520,"period":"2023-12-31"},{"value":2230520,"period":"2023-12-31"},{"value":2523383,"period":"2022-12-31"},{"value":2523383,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7219437,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":2404519,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":5597232,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}